A Phase 4 interventional study of Donepezil hydrochloride and Donepezil matching placebo in Dementia Associated With Cerebrovascular Disease, sponsored by Eisai Co., Ltd.. Completed at 31 sites in Korea, Republic of. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2020-01-10.
Sponsored by Eisai Co., Ltd. · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Cerebrovascular Disorders with a site in Korea, Republic of — 1 open to participants now, 3 under way, 1 of them phase 3. Cerebrovascular Disorders · Korea, Republic of.
Among the 13 studies in Cerebrovascular Disorders with a site in Korea, Republic of, this one is the 6th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2013, is one of 2 in phase 4, and was the 4th registered.
450 studies on the registry are indexed under Cerebrovascular Disorders; 127 are open to participants now.
Browse Cerebrovascular Disorders studies →1 of the 13 studies in Cerebrovascular Disorders with a site in Korea, Republic of is open now. Recruiting first, the newest first:
Hanyang University Guri Hospital · Sites in Korea, Republic of
Ages 19+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 94 Cerebrovascular Disorders studies recruiting now, 54 (57%) set no upper age limit and 12 (13%) stop at 75 or younger; 9 take children under 18; 19 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 5 · Phase 4 2
First in 2010; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 302 is above the median of 100 across 274 interventional studies indexed under Cerebrovascular Disorders.
Median enrollment 310 across the 10 interventional studies, 119 across the 3 observational. Of the 6 that completed or were terminated, 3 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 13 have an industry lead sponsor. The 10 most frequent:
Eisai Co., Ltd. is the lead sponsor of 152 studies on the registry; 5 are open to participants now.
Eisai Co., Ltd. has 1 study filed under Cerebrovascular Disorders — fewer than ten, so there is no comparison to draw.
1 of the studies in Cerebrovascular Disorders with a site in Korea, Republic of that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07687706Phase 3Hanyang University Guri HospitalTegoprazan for Prevention of Gastrointestinal Complication in Ischemic Stroke Patients on Antiplatelet Therapy (TegoStroke) | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Cerebrovascular Disorders with a site in Korea, Republic of, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objectives are to confirm that donepezil hydrochloride has superior efficacy compared with placebo in improving cognitive function, as measured by Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-cog), and to demonstrate that donepezil hydrochloride has superior efficacy compared with placebo in improving global function, as measured by Clinician's Interview-Based Impression of Change-plus Caregiver Input (CIBIC-plus), in patients with dementia associated with cerebrovascular disease (VaD).
This is a multi-center, randomized, double-blind, placebo-controlled, parallel-group study with an open-label extension. The study consists of 3 phases; screening phase (1 to 4 weeks), double-blind phase (24 weeks), and Open-label extension phase (24 weeks). Participants, who have completed the double-blind phase and want to continue the study participation, can be enrolled in the 24-week open-label extension phase.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients who meet all of the following criteria will be eligible for inclusion in the study:
Exclusion Criteria
Patients who meet any of the following criteria will be excluded:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive donepezil matching placebo, once daily in the evening during the double blind period.
Drug: Donepezil matching placebo
Participants will receive donepezil 5 milligram (mg), once daily in the evening during the titration phase and then the dose will be increased to 10 mg at Week 4 during the double blind period. During the maintenance period, dose reduction to 5 mg/day will be permitted only when 10 mg/day is intolerable due to adverse events.
Drug: Donepezil hydrochloride
All participants who will complete the double-blind phase and want to continue the study participation, can be enrolled in the 24-week open-label extension phase. In this phase, treatment will be initiated at 5 mg/day, and the dose will be maintained until Week 6 (Day 28-42). After assessing clinical response during the period by examination, the dose can be increased to 10 mg/day. Dose reduction (from 10 mg/day to 5 mg/day) will be permitted when the investigator judges it difficult to continue the 10 mg/day administration. It will be possible to increase the dose to 10 mg/day again.
Drug: Donepezil hydrochloride
Also known as: E2020, Aricept
Also known as: E2020, Aricept
Double Blind (DB) Phase: Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog) Score (LOCF) at Week 24
The ADAS-Cog was a validated psychometric instrument that evaluates memory (word recall, word recognition), attention, reasoning (following commands), language (naming, comprehension), orientation, ideational praxis (placing letter in envelope) and constructional praxis (copying geometric designs). The ADAS-cog scores range from 0 to 70, with negative change from baseline indicating clinical improvement. LOCF=last observation carried forward.
Time frame: Baseline and Week 24
Double Blind (DB) Phase: Clinicians Interview-based Impression of Change-plus Caregiver Input (CIBIC-plus) Score (LOCF)
The CIBIC-plus rates change in global functioning relative to baseline on a scale. The score ranges from 1 (Marked improvement) to 7 (Marked worsening). A score of "4" represents no change from baseline. LOCF=last observation carried forward.
Time frame: Week 24
Double Blind (DB) Phase: Change From Baseline in Mini-mental State Examination (MMSE) Score (LOCF) at Week 24
MMSE is a well-known, gold standard test for measuring the cognitive state of dementia participants. It includes items evaluating orientation to time and place, recall of objects, attention, language, and conversational abilities. The total score ranges from 0 (most impaired) to 30 (no impairment). The lower score means severe cognitive deficit. A positive change score indicated improvement from baseline. LOCF=last observation carried forward.
Time frame: Baseline and Week 24
Double Blind (DB) Phase: Change From Baseline in Executive Function Test (Korean Trail Making Test Elderly [K-TMT-e]) Score (LOCF) at Week 24
The trail making test (TMT) was an evaluation tool used to assess the cognitive function, especially for executive function. The K-TMT-e has two parts that are referred to as part A (component: serial numbers) and part B (component: serial numbers and days). The K-TMT-e was a timed test and the goal was to complete the tests accurately and as quickly as possible. Higher scores reveal greater impairment. K-TMT-e Score was measured as time taken by participants to complete goal. LOCF=last observation carried forward.
Time frame: Baseline and Week 24
Participants took part in the study at 32 investigative sites in Korea from 05 August 2013 to 21 December 2018.
| Milestone | Placebo in DB Phase Then Donepezil in OLE Phase | Donepezil in DB Phase Then Donepezil in OLE Phase |
|---|---|---|
| Started | 154 | 148 |
| Treated/safety set | 153 | 147 |
| Completed | 130 | 122 |
| Not completed | 24 | 26 |
| Withdrew: Protocol violation | 1 | 5 |
| Withdrew: Withdrawal by subject | 15 | 12 |
| Withdrew: Adverse event | 8 | 9 |
| Milestone | Placebo in DB Phase Then Donepezil in OLE Phase | Donepezil in DB Phase Then Donepezil in OLE Phase |
|---|---|---|
| Started | 86 | 75 |
| Safety set | 86 | 75 |
| Completed | 83 | 66 |
| Not completed | 3 | 9 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 4 |
| Withdrew: Adverse event | 1 | 3 |
| Withdrew: Other | 0 | 1 |
The ADAS-Cog was a validated psychometric instrument that evaluates memory (word recall, word recognition), attention, reasoning (following commands), language (naming, comprehension), orientation, ideational praxis (placing letter in envelope) and constructional praxis (copying geometric designs). The ADAS-cog scores range from 0 to 70, with negative change from baseline indicating clinical improvement. LOCF=last observation carried forward.
| score on a scale | Double Blind (DB) Phase: Placebo | Double Blind (DB) Phase: Donepezil |
|---|---|---|
| Double Blind (DB) Phase: Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog) Score (LOCF) at Week 24 | -2.06 ± 0.42 | -2.64 ± 0.44 |
The CIBIC-plus rates change in global functioning relative to baseline on a scale. The score ranges from 1 (Marked improvement) to 7 (Marked worsening). A score of "4" represents no change from baseline. LOCF=last observation carried forward.
| score on a scale | Double Blind (DB) Phase: Placebo | Double Blind (DB) Phase: Donepezil |
|---|---|---|
| Double Blind (DB) Phase: Clinicians Interview-based Impression of Change-plus Caregiver Input (CIBIC-plus) Score (LOCF) | 3.85 ± 0.07 | 3.73 ± 0.07 |
MMSE is a well-known, gold standard test for measuring the cognitive state of dementia participants. It includes items evaluating orientation to time and place, recall of objects, attention, language, and conversational abilities. The total score ranges from 0 (most impaired) to 30 (no impairment). The lower score means severe cognitive deficit. A positive change score indicated improvement from baseline. LOCF=last observation carried forward.
| score on a scale | Double Blind (DB) Phase: Placebo | Double Blind (DB) Phase: Donepezil |
|---|---|---|
| Double Blind (DB) Phase: Change From Baseline in Mini-mental State Examination (MMSE) Score (LOCF) at Week 24 | 0.59 ± 0.22 | 1.23 ± 0.22 |
The trail making test (TMT) was an evaluation tool used to assess the cognitive function, especially for executive function. The K-TMT-e has two parts that are referred to as part A (component: serial numbers) and part B (component: serial numbers and days). The K-TMT-e was a timed test and the goal was to complete the tests accurately and as quickly as possible. Higher scores reveal greater impairment. K-TMT-e Score was measured as time taken by participants to complete goal. LOCF=last observation carried forward.
| seconds | Double Blind (DB) Phase: Placebo | Double Blind (DB) Phase: Donepezil |
|---|---|---|
| Part A | -5.10 ± 4.38 | -12.82 ± 4.52 |
| Part B | 1.16 ± 5.41 | -13.73 ± 5.52 |
Collected over From the first dose of study drug to 30 days after the last dose of study drug (up to 52 weeks [DB Phase: From the first dose of study drug till Week 24; OLE Phase: Post Week 24 till Week 52]). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double Blind (DB) Phase: Placebo | 1/153 (0.7%) | 24/153 (15.7%) | 73/153 (47.7%) |
| Double Blind (DB) Phase: Donepezil | 1/147 (0.7%) | 18/147 (12.2%) | 86/147 (58.5%) |
| Open Label Extension (OLE) Phase: Donepezil | 2/161 (1.2%) | 12/161 (7.5%) | 63/161 (39.1%) |
| Event | Double Blind (DB) Phase: Placebo | Double Blind (DB) Phase: Donepezil | Open Label Extension (OLE) Phase: Donepezil |
|---|---|---|---|
| Angina pectorisCardiac disorders | 0/153 | 1/147 | 0/161 |
| Gastritis erosiveGastrointestinal disorders | 0/153 | 1/147 | 0/161 |
| HaematocheziaGastrointestinal disorders | 0/153 | 1/147 | 0/161 |
| AstheniaGeneral disorders | 0/153 | 1/147 | 0/161 |
| Cholecystitis acuteHepatobiliary disorders | 0/153 | 1/147 | 0/161 |
| SepsisInfections and infestations | 1/153 | 1/147 | 0/161 |
| GastroenteritisInfections and infestations | 0/153 | 1/147 | 0/161 |
| Subcutaneous abscessInfections and infestations | 0/153 | 1/147 | 0/161 |
| Upper limb fractureInjury, poisoning and procedural complications | 1/153 | 1/147 | 1/161 |
| LacerationInjury, poisoning and procedural complications | 0/153 | 1/147 | 0/161 |
| Event | Double Blind (DB) Phase: Placebo | Double Blind (DB) Phase: Donepezil | Open Label Extension (OLE) Phase: Donepezil |
|---|---|---|---|
| Decreased appetiteMetabolism and nutrition disorders | 5/153 | 11/147 | 0/161 |
| NauseaGastrointestinal disorders | 3/153 | 10/147 | 5/161 |
| HeadacheNervous system disorders | 7/153 | 9/147 | 5/161 |
| NasopharyngitisInfections and infestations | 9/153 | 6/147 | 4/161 |
| InsomniaPsychiatric disorders | 1/153 | 7/147 | 1/161 |
| VomitingGastrointestinal disorders | 1/153 | 6/147 | 1/161 |
| DizzinessNervous system disorders | 6/153 | 5/147 | 3/161 |
| DiarrhoeaGastrointestinal disorders | 4/153 | 5/147 | 1/161 |
| CoughRespiratory, thoracic and mediastinal disorders | 5/153 | 1/147 | 2/161 |
| Abdominal painGastrointestinal disorders | 2/153 | 4/147 | 2/161 |
The Full Analysis Set (FAS) was the group of randomized participants who received at least one dose of study drug and had at least one postdose primary efficacy measurement.
| Age, Continuous(years) | Double Blind (DB) Phase: Placebo | Double Blind (DB) Phase: Donepezil | Total |
|---|---|---|---|
| Mean | 72.96 ± 7.94 | 72.31 ± 7.06 | 72.64 ± 7.52 |
| Sex: Female, Male(Participants) | Double Blind (DB) Phase: Placebo | Double Blind (DB) Phase: Donepezil | Total |
|---|---|---|---|
| Female | 55 | 48 | 103 |
| Male | 91 | 89 | 180 |
| Race/Ethnicity, Customized(Participants) | Double Blind (DB) Phase: Placebo | Double Blind (DB) Phase: Donepezil | Total |
|---|---|---|---|
| Korean | 146 | 137 | 283 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2013 to primary completion in Jul 2018, 59 months.
Results were first posted in Oct 2019, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Donepezil